Evidence map›Paper›PMID 34724178›Full record

ReviewJournal of microbiology (Seoul, Korea)2021

Phytochemicals for the treatment of COVID-19.

Erica Españo, Jiyeon Kim, Kiho Lee, Jeong-Ki Kim

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of microbiology (Seoul, Korea), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Current drug discovery technologies · 2024
    Article
  3. Review
  4. Review
  5. International journal of molecular sciences · 2022
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Paemi Sino · 2022
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erica EspañoDepartment of Pharmacy, Korea University College of Pharmacy, Sejong, 30019, Republic of Korea.
Jiyeon KimDepartment of Pharmacy, Korea University College of Pharmacy, Sejong, 30019, Republic of Korea.
Kiho LeeDepartment of Pharmacy, Korea University College of Pharmacy, Sejong, 30019, Republic of Korea.
Jeong-Ki KimDepartment of Pharmacy, Korea University College of Pharmacy, Sejong, 30019, Republic of Korea. jkfrancis@korea.ac.kr.
Korea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has underscored the lack of approved drugs against acute viral diseases. Plants are considered inexhaustible sources of drugs for several diseases and clinical conditions, but plant-derived compounds have seen little success in the field of antivirals. Here, we present the case for the use of compounds from vascular plants, including alkaloids, flavonoids, polyphenols, and tannins, as antivirals, particularly for the treatment of COVID-19. We review current evidence for the use of these phytochemicals against SARS-CoV-2 infection and present their potential targets in the SARS-CoV-2 replication cycle.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentPandemicsPhytochemicalsAnimalsChlorocebus aethiopsHEK293 CellsHumansSARS-CoV-2Vero CellsAntiviral AgentsPhytochemicalsalkaloidsantiviralscoronavirusesCOVID-19flavonoidsnatural productsphytochemicalsSARS-CoV-2

Identifiers

PMID34724178
PMCPMC8559138
OpenAlexW3208789597

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.